MARKET

SLXNW

SLXNW

Silexion Therapeutics Corp
NASDAQ
0.0120
-0.0035
-22.58%
Closed 13:52 05/15 EDT
OPEN
0.0154
PREV CLOSE
0.0155
HIGH
0.0154
LOW
0.0120
VOLUME
1.00K
TURNOVER
--
52 WEEK HIGH
0.1508
52 WEEK LOW
0.0104
MARKET CAP
--
P/E (TTM)
-0.0013
1D
5D
1M
3M
1Y
5Y
1D
Silexion Therapeutics sells unregistered warrants for 3990184 shares at $0.5 each
PUBT · 22h ago
Silexion Therapeutics says warrant exercises raise USD 1 million gross proceeds
PUBT · 1d ago
SILEXION THERAPEUTICS REPORTS POSITIVE PRELIMINARY IMMUNOTHERAPY FINDINGS FOR SIL204 IN KRAS-DRIVEN PANCREATIC CANCER
Reuters · 2d ago
Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer
PUBT · 3d ago
Weekly Report: what happened at SLXNW last week (0504-0508)?
Weekly Report · 5d ago
Weekly Report: what happened at SLXNW last week (0427-0501)?
Weekly Report · 05/04 09:36
Silexion submits Germany trial application for SIL204 pancreatic cancer study
PUBT · 04/28 12:45
Weekly Report: what happened at SLXNW last week (0420-0424)?
Weekly Report · 04/27 09:36
More
About SLXNW
Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXNW stock methods without spending real money on the virtual paper trading platform.